Serpins, New Therapeutic Targets for Hemophilia
- 28 September 2020
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 121 (03), 261-269
- https://doi.org/10.1055/s-0040-1716751
Abstract
Hemostasis is a tightly regulated process characterized by a finely tuned balance between procoagulant and anticoagulant systems. Among inherited hemostatic conditions, hemophilia is one of the most well-known bleeding disorders. Hemophilia A (HA) and B (HB) are due to deficiencies in coagulation factor VIII (FVIII) or FIX, respectively, leading to unwanted bleeding. Until recently, hemophilia treatment has consisted of prophylactic replacement therapy using plasma-derived or recombinant FVIII in cases of HA or FIX in cases of HB. Because FVIII and FIX deficiencies lead to an imbalance between procoagulant and anticoagulant systems, a recent upcoming strategy implies blocking of endogenous anticoagulant proteins to compensate for the procoagulant factor deficit, thus restoring hemostatic equilibrium. Important physiological proteins of the anticoagulant pathways belong to the serpin (serine protease inhibitor) family and, recently, different experimental and clinical studies have demonstrated that targeting natural serpins could decrease bleeding in hemophilia. Here, we aim to review the different, recent studies demonstrating that blocking serpins such as antithrombin, protein Z-dependent protease inhibitor, and protease nexin-1 or modifying a serpin like α1-antitrypsin could rebalance coagulation in hemophilia. Furthermore, we underline the potential therapeutic use of serpins for the treatment of hemophilia. ∗ K.A. and C.K. contributed equally to this article. Received: 14 February 2020 Accepted: 07 August 2020 Article published online: 28 September 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyFunding Information
- INSERM, Université de Paris
- CSL Behring-SFH, the Agence Nationale de la Recherche (ANR-14-OHRI-0013)
- Bayer Hemophilia Award Program
- National Blood Foundation
This publication has 46 references indexed in Scilit:
- Characterization of the Heparin-Binding Site of the Protein Z-Dependent Protease InhibitorBiochemistry, 2012
- Serpin structure, function and dysfunctionJournal of Thrombosis and Haemostasis, 2011
- Heparin Is a Major Activator of the Anticoagulant Serpin, Protein Z-dependent Protease InhibitorOnline Journal of Public Health Informatics, 2011
- Exosite Determinants of Serpin SpecificityOnline Journal of Public Health Informatics, 2009
- Interpatient Phenotypic Inconsistency in Severe Congenital Hemophilia: A Systematic Review of the Role of Inherited ThrombophiliaSeminars in Thrombosis and Hemostasis, 2009
- Protein Z–dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiencyBlood, 2008
- Antithrombin Affects Hemostatic Response to Recombinant Activated Factor VII in Factor VIII Deficient PlasmaAnesthesia & Analgesia, 2008
- Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patientsBritish Journal of Haematology, 2007
- Serpins in thrombosis, hemostasis and fibrinolysisJournal of Thrombosis and Haemostasis, 2007
- Peptidomimetic inhibitors for activated protein C: implications for hemophilia managementJournal of Thrombosis and Haemostasis, 2006